Anfield Capital Management, LLC Crispr Therapeutics Ag Transaction History

Anfield Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	BUY	$61.1 - $83.78 $1,099 - $1,508	18 Added 4.83%	391 $26,000
Q2 2022 Aug 09, 2022	BUY	$43.23 - $73.83 $3,112 - $5,315	72 Added 23.92%	373 $23,000
Q1 2022 May 13, 2022	BUY	$53.19 - $79.24 $8,776 - $13,074	165 Added 121.32%	301 $19,000
Q4 2021 Feb 03, 2022	BUY	$70.09 - $111.29 $8,761 - $13,911	125 Added 1136.36%	136 $10,000
Q3 2021 Nov 04, 2021	BUY	$110.2 - $156.64 $1,212 - $1,723	11 New	11 $1,000

489

57.9M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.16B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Anfield Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Anfield Capital Management, LLC with notifications on news.